Robert Breedlove
Fortuna: 493 896 $ al 30/09/2026
Fortuna: 493 896 $ al 30/09/2026
Robert Breedlove is Chief Accounting Officer & Vice President-Finance at Phathom Pharmaceuticals, Inc. since 2025.
Former roles include Manager-Financial Reporting & Compliance at NeoGenomics, Inc. and Senior Manager at Van Den Boom & Associates LLC.
Education includes an undergraduate degree from the University of San Diego.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 03/09/2026 | 67.657 ( 0,08 % ) | 493 896 $ | 30/09/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 06/10/2025 |
| Empresas | Cargo | Fin |
|---|---|---|
| NEOGENOMICS, INC. | Oficial de Cumplimiento | - |
Van Den Boom & Associates LLC
Van Den Boom & Associates LLC Miscellaneous Commercial ServicesCommercial Services Provides accounting, financial, payroll, benefit and human resource services | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
NeoGenomics, Inc.
NeoGenomics, Inc. Medical/Nursing ServicesHealth Services Provides genetic and molecular testing services | Health Services |
University of San Diego
University of San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Van Den Boom & Associates LLC
Van Den Boom & Associates LLC Miscellaneous Commercial ServicesCommercial Services Provides accounting, financial, payroll, benefit and human resource services | Commercial Services |
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel treatments for gastrointestinal diseases and disorders | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.